Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to select the dose of AVE1642 to be administered in patients with liver carcinoma not eligible for local treatment.

The secondary objectives of the study are:

* To evaluate the safety profile of AVE1642 as single agent and the safety profile of combinations with other anti-cancer therapies of interest in liver carcinoma , including detection of immunogenicity.
* To evaluate pharmacokinetics and pharmacodynamics profiles of AVE1642 as single agent or any PK interactions when given in combination with other anti-cancer therapies.
* To assess the preliminary clinical activity in terms of response rate (Complete response + Partial response), duration of responses, stabilisation rate and duration of stabilisation, according to RECIST criteria.
* To assess the biological activity at the tumor level.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

NCT04770896

Unresectable Hepatocellular Carcinoma

ACTIVE_NOT_RECRUITING PHASE3

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

NCT03434379

Carcinoma, Hepatocellular

COMPLETED PHASE3

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)

NCT04563338

Hepatocellular Carcinoma Non-small Cell Lung Cancer Metastatic Liver Metastases

RECRUITING PHASE2

A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

NCT00605722

Liver Cancer

COMPLETED PHASE2

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

NCT00946153

Hepatocellular Carcinoma

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AVE1642 will be administered as an IV infusion on day 1 and then every 3 weeks for at least 2 infusions for evaluability requirements. Curative and / or prophylactic management of allergic reactions during infusion will be implemented when needed. The duration of the study for one patient will include a period for inclusion of up to 2 weeks, at least 2 cycles of treatment in dose escalation step (one cycle of AVE1642 alone and at least one cycle of AVE1642 in combination) and at least one cycle of the combination in the extension cohort, followed, when possible, by a minimum of 30-day follow-up after the last drug administration, in order to detect any potential immunogenicity. In the second step, the patients will continue treatment until disease progression, unacceptable toxicity or willingness to stop.

The expected enrolment period is 15 months with at least 30 day follow-up after the last patient treated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type DRUG

oral intake

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AVE1642

intravenous infusion

Intervention Type DRUG

sorafenib

oral intake

Intervention Type DRUG

erlotinib

oral intake

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nevaxar Tarceva

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients not eligible for surgical resection, liver transplantation, local ablation techniques or chemoembolisation and with histologically proven liver carcinoma whenever possible or combination of radiologically documented hypervascular liver tumour and α foeto protein level ≥ 400 ng/ml
* Signed and dated approved patient informed consent form prior to enrollment into the study

Exclusion Criteria

* ECOG performance status \> 2
* Inadequate organ function:

* Neutrophils (ANC) \< 1,500/mm3
* Hemoglobin \< 10g/dl
* Platelets \< 100,000/mm3
* Total bilirubin \> 1.5 x ULN
* ASAT, ALAT \> 3 x ULN
* Creatininemia \> 1.5 x ULN (or ≥ 2.0 mg/dl)
* INR \> 1.6
* Liver cirrhosis Child Pugh B or C (score \> 6)
* HbA1C \> 8%
* No measurable or evaluable tumoral lesion
* Patients not eligible for sorafenib therapy and for whom this therapy cannot be postponed by 3 weeks (during AVE1642 single treatment period) in dose escalation part
* Prior exposure to an anti-IGF-1R class compound

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No